Get the Stockscreener App
23.81
10.13%
2.19
After Hours:
24.48
0.67
+2.81%
Amphastar Pharmaceuticals Inc stock is traded at $23.81, with a volume of 1.00M.
It is up +10.13% in the last 24 hours and up +5.35% over the past month.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$21.62
Open:
$22.29
24h Volume:
1.00M
Relative Volume:
1.97
Market Cap:
$1.12B
Revenue:
$723.55M
Net Income/Loss:
$157.72M
P/E Ratio:
7.9367
EPS:
3
Net Cash Flow:
$170.15M
1W Performance:
+12.26%
1M Performance:
+5.35%
6M Performance:
-26.44%
1Y Performance:
-45.96%
1-Day Range:
$22.07
$24.70
1-Week Range:
$20.70
$24.70
52-Week Range:
$20.39
$53.95
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
23.81 | 981.44M | 723.55M | 157.72M | 170.15M | 3.00 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
Utah Medical Products Reports Q2 Decline - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $25.00 by Analysts at Piper Sandler - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Pfizer beats in Q2 earnings, reaffirms 2025 outlook [Video] - AOL.com
XTX Topco Ltd Takes Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Interpace Biosciences Earnings Drop - AOL.com
Amphastar Pharmaceuticals Inc (AMPH) Q2 2025 Earnings Call Highlights: Strong Vaccine Sales and ... By GuruFocus - Investing.com Canada
Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 500 Shares of Stock - MarketBeat
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now? - Yahoo Finance
Piper Sandler lowers Amphastar Pharmaceuticals stock price target on competitive headwinds - Investing.com Canada
Earnings call transcript: Amphastar Q2 2025 beats EPS forecast, stock rises - Investing.com Canada
Amphastar August 2025 presentation slides: long-term growth strategy faces near-term headwinds - Investing.com Canada
Amphastar Pharmaceuticals Topped Earnings And Is Doubling Down At Home - Finimize
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6% - TradingView
Atea (AVIR) Q2 Loss Narrows 8% - AOL.com
Amphastar advances U.S. manufacturing expansion and signals flat 2025 revenue outlook amid competitive pressures - MSN
Amphastar's Q2 2025: Unpacking Contradictions in BAQSIMI Growth, Manufacturing Capacity, and FDA Approvals - AInvest
Amphastar Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals Reports Q2 2025 Earnings Highlights - TipRanks
Amphastar Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amphastar (AMPH) Q2 2025 Earnings Call Transcript - AOL.com
Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
Amphastar: Q2 Earnings Snapshot - San Francisco Chronicle
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 - ACCESS Newswire
Immunocore (IMCR) Q2 Revenue Jumps 30% - AOL.com
AstraZeneca increasing focus on US market, as it is 'first to provide access to patients': CFO [Video] - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 1-Year LowWhat's Next? - MarketBeat
Amphastar Pharmaceuticals (AMPH) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) to Release Quarterly Earnings on Thursday - MarketBeat
How many analysts rate Amphastar Pharmaceuticals Inc. as a “Buy”Explosive trading growth - Jammu Links News
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by GSA Capital Partners LLP - MarketBeat
How volatile is Amphastar Pharmaceuticals Inc. stock compared to the marketFree Trading Psychology Coaching - Jammu Links News
Is it the right time to buy Amphastar Pharmaceuticals Inc. stockBuild a portfolio that outperforms the market - Jammu Links News
How does Amphastar Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results today - Jammu Links News
What makes Amphastar Pharmaceuticals Inc. stock price move sharplyInvest smarter with advanced market data - Jammu Links News
What are the technical indicators suggesting about Amphastar Pharmaceuticals Inc.High-profit trading signals - Jammu Links News
What are Amphastar Pharmaceuticals Inc. company’s key revenue driversAchieve breakthrough performance in the market - Jammu Links News
Should I hold or sell Amphastar Pharmaceuticals Inc. stock in 2025Get daily updates on the hottest stocks - Jammu Links News
What catalysts could drive Amphastar Pharmaceuticals Inc. stock higher in 2025Achieve consistent double-digit growth - Jammu Links News
When is Amphastar Pharmaceuticals Inc. stock expected to show significant growthDouble-digit growth - Jammu Links News
Why is Amphastar Pharmaceuticals Inc. stock attracting strong analyst attentionMaster the art of timing market moves - Jammu Links News
Federated Hermes Inc. Reduces Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
How strong is Amphastar Pharmaceuticals Inc. company’s balance sheetPre Market Entry Points To Watch Now - Jammu Links News
Victory Capital Management Inc. Has $2.35 Million Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
TD Asset Management Inc Increases Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):